Physician profile
John Michael Bacon
NPI 1609611730
$356.45
in general payments reported to CMS, 2019-2025
11 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $69.12 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $120.52 | 2025 | |
| Merck Sharp & Dohme LLC | $33.05 | 2025 | Winrevair |
| Boston Scientific Corporation | $32.78 | 2024-2025 | Emblem Mri S-Icd |
| Amgen INC. | $27.23 | 2024 | Repatha |
| Scpharmaceuticals INC. | $27.01 | 2024 | |
| Inspire Medical Systems, INC. | $24.55 | 2025 | Inspire |
| Stryker Corporation | $20.43 | 2025 | Artix Mt |
| Lilly USA, LLC | $20.04 | 2025 | Zepbound |
| Chiesi USA, INC. | $18.60 | 2025 | Juxtapid |
| Novo Nordisk INC | $17.63 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $14.61 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.